PELGRAZ

This brand name is authorized in Australia, Austria, Brazil, Croatia, Cyprus, Estonia, Finland, France, Ireland, Italy, Lithuania, Netherlands, Poland, Romania, Spain, UK.

Active ingredients

The drug PELGRAZ contains one active pharmaceutical ingredient (API):

1	Pegfilgrastim UNII 3A58010674 - PEGFILGRASTIM
	Pegfilgrastim is a sustained duration form of filgrastim due to decreased renal clearance. Pegfilgrastim and filgrastim have been shown to have identical modes of action, causing a marked increase in peripheral blood neutrophil counts within 24 hours, with minor increases in monocytes and/or lymphocytes.
	Read more about Pegfilgrastim

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AA13	Pegfilgrastim	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AA Colony stimulating factors
Discover more medicines within L03AA13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	6363X, 9514R
BR	Câmara de Regulação do Mercado de Medicamentos	538021020031707
EE	Ravimiamet	1780556, 1806960
ES	Centro de información online de medicamentos de la AEMPS	1181313001, 1181313002
FI	Lääkealan turvallisuus- ja kehittämiskeskus	090158, 144299
FR	Base de données publique des médicaments	61553026, 64847677
GB	Medicines & Healthcare Products Regulatory Agency	358592, 386550
IE	Health Products Regulatory Authority	88826, 88961, 89056
IT	Agenzia del Farmaco	047090016, 047090028
LT	Valstybinė vaistų kontrolės tarnyba	1086344, 1088386
NL	Z-Index G-Standaard	15007219
NL	Z-Index G-Standaard, PRK	68756
PL	Rejestru Produktów Leczniczych	100411680, 100446543
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W65705001, W66201001